Bundang CHA university global clinical trials center Institutional Review Board
Gyeonggi-do, Bundang-gu, 13497, South Korea
NCT Number: NCT06165965
To evaluate the safety and pharmacokinetic characteristics after the administration of JT-001, JT-002 and JLP-2008
Looking for future studies?
Notify Me19 year–55 year
All sexes
Interventional
Phase 1
Gyeonggi-do, Bundang-gu, 13497, South Korea
A randomized, open-label, single oral dosing, two-sequence, and two-period crossover study to evaluate the pharmacokinetics and safety between the administration of JLP-2008 and the co-administration of JT-001, and JT-002 for healthy subjects in fasted state
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
SGLT2 dual inhibitor
Time frame: 24 hours
Time frame: 24 hours
Jeil Pharmaceutical Co., Ltd.
Industry
A Randomized, Open-label, Two-sequence, and Two-period Crossover Study to Evaluate the Pharmacokinetics and Safety Between the Administration of JLP-2008 and the Co-admin. of JT-001, and JT-002 for Healthy Subjects in Fasted State
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05454007
Brain Diseases, Cardiovascular Diseases
Lebanon, Oregon, United States
View Trial DetailsNCT07717645
Alcohol Abstinence, Behavior
Mersin, Turkey (Türkiye)
View Trial DetailsNCT06818032
Healthy, Healthy Adult
Burlington, Vermont, United States
View Trial DetailsNCT07633691
Healthy Adult
Gangseo-gu, Seoul, South Korea
View Trial Details